Strategic Transformation
Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.
Entolimod Development Progress
Transferred two INDs for Entolimod, completed cell line verification, and advanced manufacturing readiness for military countermeasure and stockpile drug.
Financial Position
Cash and cash equivalents increased to $3.5 million from $2 million, with no debt on the balance sheet.
Gross Margin Improvement
Gross margins, excluding inventory reserve, improved to 42% from 35% compared to the previous year.